Infinity Pharmaceuticals, Inc.’s INFI shares plunged 69.2% to hit a new 52-week low, after the company announced unfavorable data from the phase II DYNAMO study on its lead candidate, duvelisib, for ...
Infinity Pharmaceuticals Inc (NASDAQ: INFI) reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback